Edwards CJ, et al. - A randomized, double-blind trial was done to investigate whether tocilizumab + tapering MTX has comparable effectiveness and safety vs tocilizumab + stable MTX in adult RA patients with inadequate response to MTX. It was concluded that the tapering MTX in patients with RA receiving tocilizumab was non-inferior to continuing stable MTX in maintaining a good/moderate EULAR response. No unexpected safety signals were noticed. In both groups, tocilizumab and MTX therapy were generally well tolerated.